First-Ever Epstein-Barr Virus Vaccine Shows Strong Immune Response

1
First-Ever Epstein-Barr Virus Vaccine Shows
Strong Immune Response
2
(No Transcript)
3
Scientists at the QIMR Berghofer Medical Research
Institute have achieved a groundbreaking
advancement in creating the first-ever vaccine
against the Epstein-Barr virus (EBV), responsible
for infectious mononucleosis and linked to cancer
and multiple sclerosis. The vaccine stimulates
antibodies and T cells, integral components of
the immune system, to combat EBV. It also offers
a unique defense against EBV-associated tumors,
potentially preventing secondary conditions like
brain inflammation and multiple sclerosis. The
team aims to begin human clinical trials,
expected to start around 2024 or 2025, with
initial funding secured from industry partners.
This milestone holds promise for addressing
EBV-related health concerns